SIR,-We have shown that lung tissue angiotensin converting enzyme (ACE) activity was reduced in rats with pulmonary hypertension induced by a single injection of monocrotaline (Thorax March 1982, p 198) . Lafranconi and Huxtable, however (April 1983, p 307), have suggested that this decrease in specific activity of ACE was due to an increase in total lung protein and not to an actual reduction in the total ACE activity in the lung. We have therefore recalculated our data in terms of total ACE activity per lung (nmol/min/lung). The mean (SD) value for the control group (n = 10) was 1379-9 (492-9) , and for the group treated with monocrotaline (n = 7) 657*4 (225.2). Thus there was a significant decrease in total lung ACE activity in the rats treated with monocrotaline (t = 3.597, p < 0-005). In a recent experiment' we measured angiotensin II immunoreactive material in right ventricular and aortic blood derived from control rats (n = 7) and rats given a single injection of monocrotaline (n = 5). In the control rats the mean (SD) angiotensin II levels (pg/ml) Drs Keane and Kay comment on our subacute route of administration. The advantages of this method are: it is milder in that as little as five days of the protocol will produce the same degree of pulmonary hyperplasia 21 days later as will a single injection of 60 mg/kg of monocrotaline; there is no overt liver toxicity; and the protocol avoids pulmonary oedema and inflammatory changes in the heart and lungs which are unrelated to the degree of right ventricular damage. A disadvantage of the method is that there is some variability in the dose of monocrotaline received by individual rats. However, our technique produces consistent right ventricular hypertrophy, and we use this hypertrophy as the reference point for determining the degree of damage. The consistency of the technique is shown by the fact that the ratio of right ventricular weight to that of the left ventricle plus septum is 0-561 (0.144) (mean (SD) for 36 animals).1 This is identical to the value reported by Kay etal of 0-558 (0.113). As has been elegantly demonstrated by Kay and Heath,2 there is a constant relationship between the increase in right ventricular weight, pulmonary arterial systolic blood pressure, and arterial medial thickness after exposure to pyrrolizidine. We have taken, as these authors have proposed, right ventricular weight as an index of the progression of hypertensive disease.
We would conclude the following: (i) The difference in 159 observations between ourselves and Dr Kay and his colleagues may be explicable by differences in the route of administration of monocrotaline and the size of the animals used. (ii) We find lung hyperplasia, right ventricular hypertrophy, and reductions in serotonin transport in the absence of changes in lung total ACE. (iii) If hyperplasia of an organ occurs, the expression of enzyme activities on a total organ basis is appropriate. (iv) We have observed right ventricular hypertrophy only after the development of lung hyperplasia. It is implied by Drs Keane and Kay that right ventricular hypertrophy may be obtained after monocrotaline administration in the absence of lung hyperplasia. This is an important statement, and should be appropriately documented (no data on organ weights are presented in their report), as it has a bearing on hypotheses concerning the inducement of hypertrophy. 
